Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2005

View Archived Issues

Close proximity of dopaminergic and serotonergic neurons might explain delayed effects of SSRIs

Antidiabetic effects of cytogenin in streptozotocin-induced diabetes in mice

A novel Stat3 inhibitor as a treatment for breast cancer

Pregabalin provides fast pain relief in postherpetic neuralgia

Promising results obtained with a novel formulation of dronabinol in healthy volunteers

Japanese approval for Vfend

Delay to sBLA filing for Erbitux

Enrollment under way in SYNTAX trial comparing stents to cardiac surgery

Enrollment begins in ENDEAVOR IV study

Osel initiates two Lactin-V phase II studies

Memory extends timeline for safety and tolerability study of MEM-1003

Provectus prepares to study Xantryl in psoriasis and eczema

Series A financing to support Janus pipeline progression

OMS-103HP enters phase III

7TM Pharma and P&G sign research agreement

Enrollment completed in TRIUMPH study of eculizumab for PNH

Phase I/II trial begins for SonoLysis in PAOD

Seattle Genetics inlicenses anti-CD33 antibody program from PDL

Schering-Plough to begin preclinical development of collaborative compound

Vectura and Arakis sign development deal with Novartis for AD-237 for COPD

Alnylam and Benitec sign license agreement in RNAi

Development of a stable and effective vaginal anti-HIV microbicide

New family of non-nucleoside HCMV and VZV inhibitors

NGP-1-01, a promising lead for novel neuroprotective agents

5-HT2C agonists evaluated as therapeutics for urinary disorders

Pieris and Syngenta to develop Anticalins

Recent patents disclose new therapeutic agents for diabetes

Novel agents claimed for transplant rejection and immunological disorders

Japanese approval for Follistim

Raloxifene lowers the risk of cognitive impairment in postmenopausal women

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...